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Abstract
Background: Induction-maintenance therapy is a treatment regime where patients are prescribed an intense
course of treatment for a short period of time (the induction phase), followed by a simplified long-term regimen
(maintenance). Since induction therapy has a significantly higher chance of pill fatigue than maintenance therapy,
patients might take drug holidays during this period. Without guidance, patients who choose to stop therapy will
each be making individual decisions, with no scientific basis.
Methods: We use mathematical modelling to investigate the effect of imperfect adherence during the inductive
phase. We address the following research questions: 1. Can we theoretically determine the maximal length of a
possible drug holiday and the minimal number of doses that must subsequently be taken while still avoiding
resistance? 2. How many drug holidays can be taken during the induction phase?
Results: For a 180 day therapeutic program, a patient can take several drug holidays, but then has to follow each
drug holiday with a strict, but fairly straightforward, drug-taking regimen. Since the results are dependent upon the
drug regimen, we calculated the length and number of drug holidays for all fifteen protease-sparing triple-drug
cocktails that have been approved by the US Food and Drug Administration.
Conclusions: Induction therapy with partial adherence is tolerable, but the outcome depends on the drug cocktail.
Our theoretical predictions are in line with recent results from pilot studies of short-cycle treatment interruption
strategies and may be useful in guiding the design of future clinical trials.
Background
Currently, 33 million people worldwide are infected with
HIV/AIDS, of whom 2.7 million were infected in 2007
[1]. HIV is a disease that is accompanied by a profound
depletion in the number of CD4
+ T cells and can be
transmitted by blood or other body fluids [2]. Most
patients with HIV/AIDS are prescribed a triple-drug
cocktail with either three nucleoside-analogue reverse
transcriptase inhibitors (RTIs), or two RTIs and one
protease inhibitor (PI) [3]. However, PI-sparing cocktails
have been shown to have equivalent potency to PI-con-
taining cocktails [4] and may reduce the risk of meta-
bolic and potential cardiovascular consequences of PI-
containing therapy, while providing similar or improved
virologic control and durability of effect [5].
The importance of adherence to HIV drug regimens
presents challenges that arise from the biology of HIV,
the magnitude of the required therapeutic effort and the
changing demography of HIV infection [6]. In order to
determine regimens for partial adherence, a number of
mathematical models have attempted to quantify how
drug concentration levels in the body of an HIV patient
affect viral replication [7-13].
Adherence to drug therapy is necessary in order to
control HIV, but sometimes-overwhelming side effects,
as well as the inconvenience of following a strict regi-
men, deter patients from taking their drugs [14]. Imper-
fect or partial adherence can facilitate the emergence of
drug-resistant mutations [15].
Induction therapy is a HIV/AIDS treatment regime
that hopes to benefit patients by decreasing drug resis-
tance and reducing the overall number of drugs that
must be taken. In order to minimise drug resistance,
induction-maintenance (IM) therapy strategies begin
with a period of intensified antiretroviral therapy (induc-
tion phase), followed by a simplified, long-term regimen
(maintenance phase) [16-19].
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uncalculated latently infected cells and imperfect adher-
ence [17,19]. Recently, however, Curlin et al. [20] have
shown that a longer induction phase decreases the prob-
ability that viruses resistant to maintenance therapy will
emerge. Their studies have shown that the probability of
success (maintaining a suppressed, circulating, free-virus
population for a period of at least 3 years after the end
of induction therapy) varies with the length and time of
the induction phase [20]. Using a stochastic model, it
was shown that induction therapy would have to last at
least 180 days for cocktails containing two RTI-like
drugs and a PI-like drug [20,21].
Imperfect adherence has led to failure in suppressing
viral replication and often mutations develop before or
during induction therapy [6]. Since induction therapy
has a significantly higher chance of pill fatigue than
maintenance therapy, it is likely the patients will take
some holidays during this period. Scientific literature
cautions patients against taking any holidays while on
therapy [22], but many patients are underadherent or
nonadherent [23,24]. Without guidance, patients who
choose to stop therapy will each be making individual
decisions, with no scientific basis. Recently, the question
of short-term holidays (such as weekends) have been
examined. Patients were highly adherent to five days on/
two days off (FOTO) therapy. When asked about their
preference for this type of therapy versus continuous
HAART (Highly Active Antiretroviral Therapy), on a
10-point scale, the mean response was 9.7 [25].
Here, we examine the effects of imperfect adherence
during the induction phase using a mathematical model
of impulsive differential equations. We use the model to
address the following research questions: 1. Can we
determine the maximal length of a drug holiday and the
number of subsequent doses that must be taken to
avoid resistance? 2. How many drug holidays can be
taken during the induction phase?
Methods
Modelling drug therapy
W h e nm o d e l l i n gd r u gt h e r a p ya n dt r y i n gt oa p p r o x i -
mate the number of doses a patient can miss without
gaining drug resistance, it is important to have a reliable
threshold that will guarantee that viral replication will
not exceed a safe limit and so that the mutant strain
will not appear. The inhibition of viral replication, s, can
be described by
st
Rt
Rt I C
()
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()
, 
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where R(t) is the drug and IC50 is the concentration of
drug which inhibits viral replication by 50% [7].
Thus, when s ≈ 0, the drug has no effect, while if s ≈ 1,
the drug completely inhibits viral replication. See Figure 1.
Thus, the antiretroviral drug effect can be split into
three regions: in Region 1, drug levels are insufficient to
control either the wild-type or the mutant strain. In
Region 2, drug levels are sufficient to control the wild-
type strain but not a 10-fold mutant strain of the virus
(ie a mutant strain that requires ten times the amount
of drug to be controlled). In Region 3, drug levels are
sufficient to control replication of both virus strains.
These findings provide a threshold above which resistant
viruses will be eradicated. We let R2 be the threshold
between Regions 2 and 3.
The mathematical model
We adapt the mathematical model used from Smith &
Wahl [26], to include latently infected cells [27]:
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In these equations, VI and VY denote the wild-type
and mutant virus respectively, VNI denotes the non-
infectious virus, TS denotes the susceptible CD4
+ T
cells, TI denotes CD4
+ T cells infected by the wild-type
virus, denotes TLI denotes CD4
+ T cells latently infected
by the wild-type virus, TY denotes CD4T
+ T cells
infected by the mutant virus, TLY denotes CD4
+ T cells
latently infected by the mutant virus, TRY denotes the
noninfected CD4
+ T cells which have absorbed enough
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to prevent infection from the mutant strain, TRY denotes
the noninfected CD4
+ T cells which have absorbed
enough drug to prevent infection from both virus
strains, t is the time in days, nI is the number of virions
produced per infected cell per day, ω is the fraction of
virions produced per day by an infected CD4
+ T cell, dV
is the clearance rate of free virus, rI i st h er a t ea tw h i c h
a susceptible cell becomes infected by the wild-type
strain, rY is the rate at which a susceptible cell becomes
infected by the mutant strain, dS is the death rate of
noninfected CD4
+ T cells, dI is the death rate of infected
CD4
+T cells, ψ is the proportion of cells which become
latently infected, pL is the rate at which latently infected
cells become productive, rP is the rate at which the drug
inhibits the wild-type T cells when drug concentrations
are in Region 2, and rR and rQ are the rates at which the
drug inhibits the wild- type and drug-resistant T cells,
respectively, when drug concentrations are in Region 3.
The constant l is the birth rate of CD4
+ T cells, while
mRI and mRY are the rates at which the drug is cleared
from the intracellular compartment for intermediate and
high drug concentrations, respectively. For parameter
values and references, see [26].
The dynamics of a drug can be modelled using impul-
sive differential equations. The exponential decay can be
written as a differential equation, where R(t) is the drug
concentration during induction therapy. The dynamics
of the drug are
dR
dt
dR t t rk   ,
with impulsive conditions, at times t = tk,
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T h er a t ea tw h i c ht h ed r u gi sc l e a r e di sdr and R
i is
the dosage. Assuming a drug is taken at time tk,b yt h e
definition of an impulsive effect, we have
Rt Rt R kk
i () () .
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Determining the Region 2 threshold
To find R2, the Region 2 threshold, we determined the
time taken for resistance levels to reach a minimum.
The drug levels at this time were evaluated from the
antiretroviral effect curves and used as the R2 threshold.
This ensures that, when a drug holiday occurs, resis-
tance levels are guaranteed to be low. Missing several
Figure 1 Dose-effect curves. Example of dose-effect curves for the wild-type (solid blue curve) and 10-fold resistance (dashed green curve)
virus strains. When drug concentration levels are in Region 1, the amount of drug is insufficient to either control wild-type or mutant strains.
When drug concentration levels are in Region 2, the amount of drug is sufficient to block the wild-type virus but resistant virus may emerge.
When drug concentration levels are in Region 3, both virus strains are controlled. This example is for the reverse transcriptase inhibitor Stavudine
(d4T).
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Page 3 of 16doses increases resistance, but, by using the local mini-
mum values, we ensure that resistance cannot emerge
when patients are not taking a drug holiday.
To determine the threshold, note that
  

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since TY (0) = 0 at the beginning of infection. It fol-
lows that the viral load is initially decreasing. If the viral
load reaches a minimum at time t ,t h e nd e f i n eR2 = R
( t ). This ensures that  Vt Y() <0f o r0< t < t .I ft h e
viral load decreases indefinitely, then we could define R2
to be any value of R less than the trough value of the
periodic orbit of the drug dynamics. However, this case
is not realistic, since the virus does not clear on its own.
We define R1 to be the value of R such
R
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Thus, R1 = 0.1R2. See Figure 1.
Impulsive differential equations
T h ed y n a m i c so fb o t ht h ew i l d - t y p ea n dt h er e s i s t a n t
strains can be modelled using impulsive differential
equations. Impulsive differential equations consist of a
system of ordinary differential equations (ODEs),
together with difference equations. Between “impulses”,
tk, the system is continuous, behaving as a system of
ODEs. At the impulse points, there is an instantaneous
change in state in some or all of the variables. This
instantaneous change can occur when certain spatial,
temporal or spatio-temporal conditions are met. We
refer the interested reader to Bainov & Simeonov
[28-30] and Lakshmikantham et al. [31] for more details
on the theory of impulsive differential equations.
T h ec h a n g ei nd r u gc o n c e n t r a t i o nd e p e n d so n
whether a drug is taken or not. There is an instanta-
neous increase in the drug concentration immediately
after a dose is taken and then an exponential decay
while the drug is being absorbed in the body. The case
of perfect adherence is illustrated in Figure 2A. How-
ever, as long as the drug concentration level does not
drop below R2, there is a sufficient amount of drug to
control both viral strains. We can thus determine the
number of doses that can be missed and the number of
doses subsequently taken in order to stay above the R2
threshold. See Figure 2B.
The differential equations describing the virus and T
cells depend on the dynamic behaviour of the drugs. Thus,
for example, the rate of change of susceptible T cells
decreases in Regions 2 or 3 (at different rates), but not in
Region 1. The T cell and virus dynamics are continuous,
but their derivatives are not, since those derivatives
depend on the drugs, which are discontinuous. Since the
drug equations decouple from the remaining equations,
we develop theoretical results using the drug equations
and apply those results numerically to the entire model.
Results
Theoretical results
We used our model to examine the effects of imperfect
adherence on the induction phase of IM therapy. First,
it is necessary to model perfect adherence to locate the
impulsive periodic orbit in the drug levels. This provides
a region where the drug concentration level must reach
in order to sustain a low viral load. As can be seen in
Figure 2, drug levels start at zero during induction ther-
apy (since induction therapy starts at the beginning of
drug therapy). Each time a drug is taken, the dose
decays at a rate of Rt Rt e k
dtt rk () ( )
() 
 ,w h e r e Rt k ()

is the value at which the drug starts to decay instanta-
neously after the drug is ingested. Since we assume per-
fect adherence, we get
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where τ = tk+1 - tk is the (fixed) time between doses
for perfect adherence. We thus have
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Page 4 of 16Figure 2 Drug concentrations. Drug concentrations using impulsive differential equations. A. Example of drug concentration levels with perfect
adherence to therapy. Drug concentration levels fluctuate from lower endpoints (,, ) ttt 123
  to upper endpoints (,, ) ttt 123
  . Drug
concentration levels increase instantaneously after a dose is taken and decrease exponentially between doses. If all doses are taken, drug
concentration levels monotonically approach an impulsive orbit. B. Example of fluctuating drug concentration levels when missing drug doses.
Once drug concentration levels have reached the impulsive orbit () tn1
 , missing h doses results in a long exponential decay. Subsequent
adherence returns drug concentration levels to the impulsive periodic orbit before the next drug holiday occurs () tnhn 112 
 . In this example, a
patient has two drug holidays within a 30 day period.
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Therefore, assuming perfect adherence, the impulsive
orbit has endpoints
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Knowing the values of the endpoints for the impulsive
orbit after n = n1 doses, we are able to incorporate
imperfect adherence and see its effects. In order to
avoid Region 2 after missing many doses and to main-
tain an average drug concentration level within Region
3, we impose conditions to ensure proper therapy. To
guarantee successful induction therapy, after the first n1
doses are taken, we will force the lower endpoint of the
drug concentration to be within a tolerance ε1 of the
impulsive orbit. Thus, we require
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Once the drug concentration level has reached the
impulsive orbit, a patient may take a drug holiday. If h1
doses are subsequently missed (see Figure 2B), then
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In order to avoid Region 2 after h1 doses are missed,
we impose the condition Rt R nh ()
11 2 
  . This will allow
us to find the maximum number of doses a patient can
miss after being ε1 away from the impulsive orbit. This
results in
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After a patient has missed h1 doses, in order to keep
the viral replication low, they must take enough doses,
n2, to return to the impulsive orbit. In the worst-case
scenario, the exponential decay has reached Region 2;
thus, starting at R2, we get
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After n2 doses are taken, we must impose a new con-
dition that forces the drug concentration level to be ε2
away from the impulsive orbit. We need
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In order to determine the number of times a patient
can miss a fixed amount of doses, we must verify if
missing h2 doses is the same as missing h1 doses. After
missing h2 doses, we have
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Patients are able to miss h2 doses as long as their drug
concentration levels do not drop below Region 2. Thus
we repeat the same condition on h2:
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Page 6 of 16At the end of induction therapy, k doses must be
taken to ensure that, before the start of maintenance
therapy, there is sufficient drug to control viral replica-
tion. After missing h2 doses and assuming we are at
Region 2, k subsequent doses are taken and the drug
level becomes
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which is the same as the constraint for n2 as long as ε2
= ε3. If these conditions are satisfied, we are able to
guarantee that the drug concentration levels do not enter
Region 2 and significant drug resistance will not emerge.
Imperfect adherence
The number of missable and subsequent doses that
must be taken to avoid significant drug resistance for all
FDA-approved drugs that are part of a PI-sparing cock-
tail is shown in Table 1. These are defined by (1) and
(2), respectively. However, we stress that these results
are theoretical and have not been tested clinically. In
particular, it should be noted that pharmacokinetic para-
meters can vary from patient to patient.
There are fifteen FDA-approved PI-sparing triple-drug
cocktails, for which we calculated (a) the initial number
of doses that must be taken to be within a prescribed
tolerance of perfect adherence, (b) the number of doses
that could be missed without significant drug resistance
emerging and (c) the number of doses that must be
taken subsequently.
To determine the value of the prescribed tolerance, we
examined two possibilities: a tolerance of 0.1 μM and a
tolerance of 0.01 μM. That is, the number of doses is
considered sufficient if the trough value of the periodic
orbit of the drug dynamics is within 0.01 μM of the
trough value of therapy without drug holidays. We
imposed a further condition: that the mean drug con-
centration be larger than the trough value of drugs
when no drug holidays are taken. This is illustrated in
Figure 3. This ensures that, over the length of the entire
induction phase, drugs are maintained at sufficiently
high levels (see [26] for more discussion). In Figure 3A,
using a tolerance of 0.1 μM, the overall mean drug con-
centration is below the trough value during therapy.
Table 1 Missable doses and subsequent adherence.
Drug (units) R
i (μM) τ (days) T1/2
(hours)
R1 (μM) R2 (μM) maximum missable days
(theoretical)
minimum subsequent days
(theoretical)
Abacavir (ABC) 12 1/2 15 10
-1.0269 10
-0.0269 37
Didanosine (ddI) 4.65 1/2 25 10
-1.2218 10
-0.2218 5 7.5
Emtricitabine
(FTC)
7.2 1 39 10
-0.9788 10
0.0212 61 7
Lamivudine (3TC) 6 1/2 20 10
-1.1249 10
-0.1249 3.5 8.5
Stavudine (d4T) 2.144 1/2 7.5 10
-1.6383 10
-0.6383 1 2.5
Tenofivir (TDF) 1.184 1 60 10
-1.5229 10
-0.5229 10 24
Zidovudine (ZDV) 4.24 1/3 7 10
-1.6021 10
-0.6021 1.33 2.67
Delavirdine (DLV) 26.6 1/3 5.8 10
-1.4559 10
-0.4559 1.67 2.67
Efavirenz (EFV) 12.9 1 45 10
-0.8356 10
0.1644 92 2
Nevirapine (NVP) 7.5 1/2 27 10
-1.0088 10
-0.0088 5 12.5
Summary of data and theoretical results for reverse transcriptase inhibitors used for FDA-approved triple-drug therapy. All results are calculated with a mutant
that exhibits 10-fold resistance to the drug. The decay rate dr was calculated using the formula dr = 24 log(2)/T1/2, where T1/2 is the half-life. The last two columns
are the number of doses that may be missed before significant drug resistance emerges and the number that must subsequently be taken to return to within
0.01 μM of perfect adherence. We used the intracellular half-life for each drug, if known. Data for Column 1 was taken from [4142434445464748], and data from
Columns 2 and 3 were taken from the Department of Health and Human Services 2008 Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults
and Adolescents [37]
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Page 7 of 16Figure 3 Determining the prescribed tolerance.D i f f e r e n c eb e t w e e nap r e s c ribed tolerance of (A) 0.1 μM and (B) 0.01 μM for the reverse
transcriptase inhibitor Didanosine (ddI). The red line plotted on both graphs is the average drug concentration while taking drug holidays. This
was calculated using the data from Table 2. The average drug concentration in (A) is around 11 μM and has not reached the trough values
when drug holidays are excluded, whereas the average drug concentration in (B) is around 12 μM and thus exceeds the trough values during
therapy.
Miron and Smith? BMC Infectious Diseases 2010, 10:6
http://www.biomedcentral.com/1471-2334/10/6
Page 8 of 16Using a tolerance of 0.01 μM,a ss h o w ni nF i g u r e3 B ,
shows that the overall mean drug concentration is above
the trough value during therapy.
For the fifteen FDA-approved PI-sparing triple-drug
cocktails, we identified the “weakest” drugs in each cock-
tail; ie, those for which the least number of doses can be
missed. These drugs are Abacavir (ABC), Lamivudine
(3TC), Stavudine (d4T), Emtricitabine (FTC), Zidovudine
(ZDF), Didanosine (ddI) and Nevirapine (NVP). Thus, for
each cocktail, the maximal number of missable doses is
the same as that of its “weakest” drug. By combining the
steps in (b) and (c) above, it was possible to theoretically
calculate the number of drug holidays that could be
taken during the inductive phase, based on the regimen
for the “weakest” drug. See Table 2.
Since the minimum number of doses required to be
taken and the maximum number of doses allowed to be
missed follow a reliable pattern, we can extend this to fit
into a baseline induction phase of 180 days [20]. This
means, for example, that a patient taking the triple-drug
cocktail FTC/TDF/EFV can theoretically have a 6 day holi-
day, as long as each holiday is followed by 17 days of per-
fect adherence; patients can take seven such holidays
during the induction phase, and are thus able to miss a
total of 42 days out of 180. A patient taking ABC/3TC/
NVP can theoretically have sixteen drug holidays of 3 days
each in a 180 day period, as long as each holiday is imme-
diately followed by a 7 day period of strict adherence.
Numerical simulations
In order to determine the long-term effects of taking the
prescribed drug holidays, we simulated the worst-case
scenario: monotherapy to the “weakest” drug in each
combination from Table 2. This has the effect of overes-
timating the development of resistance: if no resistance
is predicted to emerge during monotherapy, then it is
unlikely to emerge during combination therapy. Conver-
sely, if resistance does emerge during monotherapy,
then there is no guarantee that it would emerge during
combination therapy, due to the presence of the other
two drugs.
We considered an extinction threshold of 2 × 10
-4 vir-
ions/mL. This corresponds to the concentration at
which the virus falls below 1 per body. Thus, missing
the maximum number of doses would theoretically lead
to extinction of both strains (at least up to the level of
detection), whereas missing more doses does not. How-
ever, it should be noted that we did not curtail the viral
dynamics at this threshold.
We used the model in Section (describing the
dynamic interaction between virus, T cells and drugs)
and the calculations in Section (summarised in Tables 1
and 2) to illustrate our theoretical results. In order to
demonstrate the effects of taking the prescribed drug
holidays, we first ran simulations where patients missed
the maximum number of doses and then took the
required number of subsequent doses; this cycle was
repeated for 180 days. Next, we ran the same simula-
tions, with the same parameters, except that one addi-
tional dose of the drug was skipped during each drug
holiday.
We performed these simulations for each of the
“weakest” drugs identified in Table 2: ABC (Figure 4),
3TC (Figure 5), d4T (Figure 6), FTC (Figure 7), ZDV
(Figure 8), ddI (Figure 9) and NVP (Figure 10). The first
figure in each case illustrates the case of missing the
maximal drug holiday and taking the minimum number
of subsequent doses. The second figure in each case
illustrates the same case, except that one additional dose
was missed during each drug holiday. The exception is
NVP, in which resistance did not emerge until three
extra doses were missed (Figure 10B, inset).
For the first case, the wild-type virus oscillated at low
levels during each drug holiday, but significant levels of
resistance did not appear. Thus, taking the required
number of doses successfully keeps the mutant strain at
low levels. Conversely, missing one extra dose per holi-
day (three in the case of NVP) resulted in a significant
buildup of resistance by the end of the induction phase.
In this case, there is a tremendous increase in the
mutant strain by the end of the inductive phase, indicat-
ing that therapy has failed. Resistance to Abacavir
increases from 10
-3 to 10
4; resistance to Lamivudine
Table 2 Number of drug holidays.
FDA-approved
combination
Number of
drug holidays
(theoretical)
Length of
each
holiday
(days)
Minimum
subsequent
therapy (days)
ABC* 3TC NVP 16 3 7
ABC* 3TC EFV 16 3 7
TDF 3TC* EFV 14 3.5 8.5
ddI 3TC* EFV 14 3.5 8.5
d4T* 3TC EFV 50 1 2.5
d4T* 3TC NVP 50 1 2.5
ddI* FTC EFV 13 5 7.5
TDF FTC* EFV 7 6 17
TDF FTC NVP* 9 5 12.5
ZDV* 3TC ABC 44 1.33 2.66
ZDV* 3TC EFV 44 1.33 2.66
ZDV* 3TC NVP 44 1.33 2.66
ZDV* 3TC TDF 44 1.33 2.66
ZDV* DLV 3TC 44 1.33 2.66
ZDV* DLV ddI 44 1.33 2.66
Summary of all FDA-approved, PI-sparing triple-drug combinations. Drugs
marked with an asterisk are the drug in their respective cocktail with the least
number of doses that may theoretically be missed (see Table 1). The number
of drug holidays, the length of each holiday and the minimum number of
subsequent days of strict adherence is thus calculated from this drug’s
missable and subsequent doses.
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Page 9 of 16increased from less than 10
-3 to 10
4; resistance to Stavu-
dine increased from 10
-3 to 10
3; resistance to Emtricita-
bine increased from 10
-3 to 10
4;r e s i s t a n c et o
Zidovudine increased from 10
-3 to 10
3;r e s i s t a n c et o
Didanosine increased from 10
-3 to 10
2; and resistance to
Nevirapine increased from 10
-3 to 10
4.
Comparison with clinical results
A number of studies have attempted to characterise the
safety of regular (and irregular) treatment interruptions,
generally referred to as structured treatment interrup-
tions (STIs). Pai et al. [22] summarised the to-date evi-
dence of STIs in patients with chronic unsuppressed
HIV infection due to drug-resistant HIV. They con-
cluded that there were no significant virologic or immu-
nologic benefit to STIs and that there is evidence that
STIs have a prolonged negative impact on CD4 response
and other disease events.
Subsequently, the SMART trial [32] examined CD4
+
guided interruptions, of an average duration of 16 months.
The DART trial [33] examined fixed 12 week interrup-
tions. Both trials showed no benefit to these treatment
interruptions. Indeed, the SMART trial was halted prema-
turely, due to significant morbidity and mortality among
participants. Holkmann et al. [34] reported a two-fold risk
Figure 4 Adherence to ABC monotherapy. A. Long-term effects of adherence to ABC monotherapy, using the prescribed adherence breaks.
The wild type (solid blue curve, left axes) and mutant (dashed green curve, right axes) populations are shown. The overall effect of the mutant
remains low. Parameters used, in addition to those in Table 1, were nI = 262.5 day
-1, ω = 0.7, rI = 0.01 day
-1, rY = 0.001 day
-1, dV = 3 day
-1, dS =
0.1 day
-1, dI = 0.5 day
-1, ψ = 0.2, pL = 0.05, rR = rQ =8 0μM
-1, day
-1, l = 180 cells μL
-1 and mRI = mRY = log(2) day
-1. Initial conditions were VI (0)
= 22000 virions mL
-1, VY ( 0 )=5×1 0
-3 virions mL
-1, TS (0) = 1000 cells day
-1 and all other initial conditions were zero. B. The effects of missing
one extra dose per drug holiday. The proportions of each type of uninfected T cell at the end of the simulation are shown in the insets.
Figure 5 Adherence to 3TC monotherapy. A. Long-term effects of adherence to 3TC monotherapy, using prescribed adherence breaks. B. The
effects of missing one extra dose. Drug parameters are as in Table 1, while all other parameters are as in Figure 4. The proportions of each type
of uninfected T cell at the end of the simulation are shown in the insets.
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Page 10 of 16of AIDS or death for patients who underwent treatment
interruptions that lasted three months or longer.
It should be noted that all these trials involved lengthy
periods of treatment interruption, of the order of weeks.
Our results here recommend signficantly shorter periods
of treatment interruption, of the order of days. Further-
more, our results predict significant increase in resis-
tance if these periods are exceeded, consistent with the
results from the majority of trials.
Shorter treatment interruptions have also been investi-
gated. A study comparing interruptions of less than 7 days
compared to longer interruptions showed that only 5% of
men who discontinued HAART for short periods increased
their HIV RNA. Conversely, men with longer interruptions
had significantly higher rates (35.7 of HIV RNA increase
[35]. Another study investigating cycles of 2-6 week fixed
interruptions observed no clinically significant benefit with
regard to viral suppression when off HAART, but also
observed no evidence for an increase of viral resistance
among patients undergoing repeated interruptions [36].
Recently, a pilot study examining five days on, two
days off (FOTO) followed patients for 48 weeks [25].
Virologic suppression was maintained in 89.6% of
patients. Combinations included 3TC/TDF/EFV, ABC/
TDF/EFV, ddI/3TC/EFV and ABC/ddI/TDF/EFV; 100%
of subjects on EFV- based regimens on the FOTO treat-
ment schedule maintained virologic suppression at
weeks 24 and 48. Combinations also included nevira-
pine- based regimens where one subject, on NVP/ABC/
3TC/ZDV, had viral rebound at week 12 that was con-
firmed at week 16 on the FOTO schedule. It was also
noted that 30% of the subjects on nevirapine-based
Figure 6 Adherence to d4T monotherapy. A. Long-term effects of adherence to d4T monotherapy, using prescribed adherence breaks. B. The
effects of missing one extra dose. Drug parameters are as in Table 1, while all other parameters are as in Figure 4. The proportions of each type
of uninfected T cell at the end of the simulation are shown in the insets.
Figure 7 Adherence to FTC monotherapy. A. Long-term effects of adherence to FTC monotherapy, using prescribed adherence breaks. B. The
effects of missing one extra dose. Drug parameters are as in Table 1, while all other parameters are as in Figure 4. The proportions of each type
of uninfected T cell at the end of the simulation are shown in the insets.
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Page 11 of 16regimens had blips of viral increase during therapy.
Other combinations included TDF/3TC/NVP, ZDV/
3TC/NVP, d4T/3TC/TDF/NVP. They also observed
excellent adherence to the FOTO treatment schedule
and a strong preference for this schedule compared to
HAART. None of the observed rebounds in viral load
were associated with the reported adherence of more
than 2 days off therapy.
These preliminary results are in line with our theoreti-
cal recommendations. For regimens that include EFV-
based regimens, all therapies included NRTIs and
NNRTIs that we recommend a maximum of more than
2 days per drug holiday, followed by at least 5 days of
s u b s e q u e n tt h e r a p y( T a b l e2 ) .T h eN V P - b a s e dr e g i m e n
with viral rebound included ZDV; our results predict
that drug holidays on such a regimen should be no
longer than 1.33 days (Figure 8). The three other NVP-
based regimens with viral blips included ZDV and d4T;
our results predict that neither would allow drug holi-
days as long as two days (Table 1).
Sensitivity to variations
Since individual patients may respond differently to
drugs, we explore the sensitivity of the number of mis-
sable doses to variations in parameters. The number of
missable doses depends on the dosing interval, the drug
decay rate, the drug concentration, the Region 2 thresh-
old and the number of initial doses, which itself depends
on the prescribed tolerance. Since we have already
explored variations in the dosing interval and the pre-
scribed decay rate, we now examine the variation with
respect to the other parameters.
Figure 8 Adherence to ZDV monotherapy. A. Long-term effects of adherence to ZDV monotherapy, using prescribed adherence breaks. B.
The effects of missing one extra dose. Drug parameters are as in Table 1, while all other parameters are as in Figure 4. The proportions of each
type of uninfected T cell at the end of the simulation are shown in the insets.
Figure 9 Adherence to ddI monotherapy. A. Long-term effects of adherence to ddI monotherapy, using prescribed adherence breaks. B. The
effects of missing one extra dose. Drug parameters are as in Table 1, while all other parameters are as in Figure 4. The proportions of each type
of uninfected T cell at the end of the simulation are shown in the insets.
Miron and Smith? BMC Infectious Diseases 2010, 10:6
http://www.biomedcentral.com/1471-2334/10/6
Page 12 of 16Figure 11 demonstrates the effect of variations in the
drug decay rate, the Region 2 threshold and the drug
concentration. Since the slope of the curves is low for
the second and third figures, we conclude that the
results are not highly sensitive to variations in the
Region 2 threshold or the drug concentration, although
small fluctuations may decrease the number of missable
days (Figure 11B and Figure 11C). The outcome is more
sensitive to variations in the drug decay rates, but is still
not highly sensitive (Figure 11A).
Discussion
It is vital to provide HIV patients with an effective drug
r e g i m e n .N o to n l yi si ti m p o r t a n tt h a tt h ed r u g sh a v ea
high effcacy, but it is also important that patients follow
a regimen that will benefit both their mental and physi-
cal states. Since there are such a large number of
patients who are unable to take their drugs regularly, it
is important to understand the impact of drug holidays
upon a patient’s ability to control the virus. Induction
therapy provides patients with the chance to submit to a
very strict, but short, period of intense drug taking, fol-
lowed by a long period of less-restrictive and more-
relaxed therapy (maintenance therapy). We have demon-
strated the effects of taking drug holidays during induc-
tion therapy. Instead of taking drugs two to three times
a day for the entire length of the induction period, we
were able to show that a patient can have drug holidays
with sometimes as much as six days off each time. This
form of treatment allows patients to take drug holidays
with very little negative effect.
However, missing more doses than stated can highly
affect the amount of resistant virus created. We have
demonstrated that there is a large increase of mutant
virus by simply missing one extra dose during each drug
holiday (three for the TDF- FTC-NVP combination).
Figure 10 Adherence to NVP monotherapy. A. Long-term effects of adherence to NVP monotherapy, using prescribed adherence breaks. B.
The effects of missing one extra dose. Drug parameters as as in Table 1, while all other parameters are as in Figure 4. In this case, both strains
are controlled. Inset: The effects of missing three extra doses. In this case, the wild-type strain is controlled, but the resistant strain emerges. The
proportions of each type of uninfected T cell at the end of the simulation are shown in the insets.
Figure 11 Sensitivity to other parameters. Sensitivity of length of
drug holiday to (A) the drug decay rate, dr, (B) the Region 2
threshold, R2, and (C) the drug concentration, R
i. Dashed lines
indicate values used in our calculations. This example is for ABC.
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as a patient does not exceed the maximum length of the
drug holiday; if they follow the prescribed regime, they
can control the effects of drug resistance. It should be
n o t e dt h a tC u r l i net al. [20] showed that an induction
phase on the order of 180-days was ideal for a triple-
drug therapy including two RTI-like drugs and one PI-
like drug. Since the results for a triple-drug therapy
including three RTIs do not show a dramatic increase in
resistant virus while taking the patterns suggested, we
used an 180 day induction phase as a baseline.
These results apply to the fifteen FDA-approved, PI-
sparing triple-drug cocktails, but simulations were only
performed for the drugs with the least number of missa-
ble doses: Abacavir, Lamivudine, Stavudine, Emtricita-
bine, Zidovudine, Didanosine and Nevirapine. Missing
one extra doses at the end of each drug holiday (three
for Nevirapine) drastically increases the amount of resis-
tant virus. However, it should be noted that the simula-
tions were for monotherapy only and thus, in a triple-
drug cocktail, the remaining two drugs inure against
resistance.
Efavirenz and nevirapine only require a single muta-
tion to confer resistance, and cross resistance affecting
these three NNRTIs is common [37]. Both Lamivudine
and Emtricitabine select for the M184V resistance muta-
tion, which confers high-level resistance to both drugs, a
modest decrease in susceptibility to Didanosine and
Abacavir, and improved susceptibility to Zidovudine,
Stavudine and Tenofovir [38]. It should be noted that
our model assumes that the mutant is always present.
By simulating the results for monotherapy, we illustrated
the worst-case scenario; this is illustrated by Figure 10B,
which shows that missing one extra dose per holiday is
not disastrous; in this example, the mutant only takes
hold when three extra doses are missed. Thus, our
results are more conservative than is strictly necessary.
Double mutation happens less frequently; emergence
of the M184V mutation is less frequent with Tenofovir/
Emtricitabine than with Zidovudine/Lamivudine, while
selection of the Lamivudine-associated M184V mutation
to the Zidovudine/Lamivudine combination has been
associated with increased susceptibility to Zidovudine
[37]. It follows that, when the combinations are taken
synchronously, the selection of mutants will be signfi-
cantly less likely than under monotherapy.
Discontinuous dosing is, of course, not realistic. There
is a delay, the time-to- peak, between taking a drug and
it reaching peak values in cells. Consequently, estimates
based on maximal concentrations and terminal plasma
half-lives could overestimate drug exposure. However,
such delays can be approximated by an instantaneous
change if the time-to-peak is sufficiently short, com-
pared to the time between doses. This approximation
has been shown to be robust, even for quite large delays
[39].
Other limitations to our model are the assumption
that the CD4
+ pool of lymphocytes is the most signifi-
cant source of HIV infection and that maintaining drug
concentrations at clinical levels results in maximal con-
trol of virus replication. However, not all HIV-suscepti-
ble tissues are equally susceptible to antiretroviral drugs.
For example, lymphoid cells in the gut are not comple-
tely suppressed [40]. These and other reservoirs will
contribute to the long-term generation of virus particles,
both during therapy and while undergoing a drug holi-
day. The relative rates of mutation or selection of resis-
tant viruses for the various drugs are modelled via the
choice of infection rate, rY, compared to the infection
rate, rI, for the wild-type strain. For numerical simula-
tions, we used the intracellular half-life of each drug, if
known; in the case of nucleosides, it is the cellular con-
centration of active nucleotide that is responsible for
inhibition of viral reverse transcription. Furthermore, we
assume that all tissues harbouring HIV are exposed to
the same concentration of drug.
Previously [13], we showed how many doses can be
missed for each PI- sparing drug, for only a single drug
holiday during any given therapy. Here, we extend this
to the case of more than one drug holiday.
Furthermore, all previous mathematical models of
adherence considered therapy without an endpoint.
Since induction therapy only occurs for a finite time, we
have to consider the viral load when induction therapy
ends. In particular, if a drug holiday coincided with the
end of induction therapy, then the induction phase
would functionally have ended at an earlier time and
m a yt h u sb es i g n i f i c a n t l yl e s se f f e c t i v e .S o m eo ft h ek e y
differences between our earlier work and the results
provided here occur due to the fact that here we use
10-fold resistance, rather than 50- fold resistance; multi-
ple holidays occur during a finite time interval; and the
tolerance used was 0.01 μM i n s t e a do f1 %o ft h em i n i -
mum value of periodic orbit; the tolerance we used here
is more conservative.
Future work will investigate the effects of imperfect
adherence to triple-drug cocktails involving protease
inhibitors. We will also investigate the compounding
effects of combination therapy in slowing the emergence
of resistance and the effect of inter-individual variances
in pharmacokinetics. Our modelling process could also
be extended to additional treatment scenarios in which
patients might be tempted to take drug holidays due to
a high pill burden, such as booster therapies or the
initial year of HAART.
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Using readily available pharmacokinetic data, we can
theoretically determine the maximal length of drug holi-
days and the number of subsequent doses that must be
taken. Since the induction phase lasts for a finite time,
we can thus determine how many drug holidays can be
taken within a 180-day induction period. Our theoretical
results are in line with recent results concerning five-
days-on/two-days-off (FOTO) for most cocktails, sug-
gesting that drug holidays may be limited to very short
breaks, rather than the longer holidays previously
examined.
We thus conclude that induction therapy with partial
adherence is tolerable, but the outcome depends on the
drug cocktail. We have also demonstrated a robust
method by which to determine therapy guidelines for
patients who are unable or unwilling to adhere comple-
tely. Treatment interruptions, if they occur, must be
short and followed by a strict period of dose taking.
Thus, while continuous therapy is preferable, FOTO
therapy is acceptable for all RTI cocktails except those
containing ZDV, d4T or DLV, which can only tolerate
extremely short drug holidays.
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